Patents Assigned to Wockhardt Ltd.
-
Patent number: 8288416Abstract: The present invention relates to oxazolidinones of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof. The invention also relates to processes for the preparation of the compound of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof, and to pharmaceutical compositions containing the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof and to methods for treating or preventing microbial infections using the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof.Type: GrantFiled: September 22, 2007Date of Patent: October 16, 2012Assignee: Wockhardt Ltd.Inventors: Vijaykumar Jadgishwar Patil, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Deepak Vijaykumar Dekhane, Mohammad Usman Shaikh, Yati Chugh, Rajesh Prabhakar Chavan, Mohammad Alam Jafri
-
Publication number: 20120202869Abstract: The invention provides a pharmaceutical composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof and at least one buffering agent. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of duloxetine. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.Type: ApplicationFiled: January 10, 2012Publication date: August 9, 2012Applicant: WOCKHARDT LTD.Inventor: Ramesh Sesha
-
Publication number: 20120196917Abstract: The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 mEq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.Type: ApplicationFiled: April 10, 2012Publication date: August 2, 2012Applicant: WOCKHARDT LTD.Inventor: Ramesh Sesha
-
Patent number: 8217058Abstract: The present invention relates to certain substituted piperidino phenyloxazolidinones. Specifically, the invention relates to geminally disubstituted piperidino phenyloxazolidinones having antimicrobial activity with improved pharmacokinetic profile. The invention also relates to processes for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating or preventing microbial infections using the compounds of the present invention.Type: GrantFiled: May 8, 2007Date of Patent: July 10, 2012Assignee: Wockhardt Ltd.Inventors: Mahesh Vithalbhai Patel, Mahesh Phansalkar, Vijaykumar Jagdishwar Patil, Milind Dattatraya Sindkhedkar, Prasad Keshav Deshpande
-
Patent number: 8206742Abstract: The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.Type: GrantFiled: January 12, 2007Date of Patent: June 26, 2012Assignee: Wockhardt Ltd.Inventors: Chandrashekhar Shriram Kandi, Girish Kumar Jain, Amit Gupta
-
Patent number: 8097594Abstract: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-? lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.Type: GrantFiled: February 24, 2009Date of Patent: January 17, 2012Assignee: Wockhardt Ltd.Inventors: Milind Dattatraya Sindkhedkar, Vijaya Narayan Desai, Rajesh Maganlal Loriya, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Rajesh Onkardas Bora, Santosh Devidas Diwakar, Ganesh Rajaram Jadhav, Shivaji Sampatrao Pawar
-
Patent number: 8093384Abstract: The invention relates to processes for the preparation of alfuzosin or pharmaceutically acceptable salts thereof in high purity. More particularly, it relates to the preparation of pure crystalline alfuzosin base. The invention also relates to pharmaceutical compositions that include the pure alfuzosin or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 14, 2006Date of Patent: January 10, 2012Assignee: Wockhardt Ltd.Inventors: Pankaj Kumar Nathani, Sunil Dnyaneshwar Narode, Mohammad Jaweed Mukarram Siddiqui
-
Patent number: 7985859Abstract: The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(?) clopidogrel. The process includes the step of reacting R(?) clopidogrel with a powered anhydrous base in one or more solvents.Type: GrantFiled: May 29, 2008Date of Patent: July 26, 2011Assignee: Wockhardt Ltd.Inventors: Jagdish Shukla, Anjum Reyaz Khan, Arvind Merwade, Mohammad Jaweed Mukarram Siddiqui, Yatendra Kumar
-
Patent number: 7771398Abstract: The present invention provides a delivery device comprising a fluid cartridge holder, housing and a piston drive mechanism that comprises a hollow piston rod and a drive-shaft. The hollow piston rod has an internal thread that mates with the external thread of the drive-shaft, forming a thread connection and being axially restrained in the proximal direction relative to the housing. The drive mechanism is in turn connected to the housing via a one way ratchet such that the piston rod is prevented from moving in the proximal direction.Type: GrantFiled: December 30, 2005Date of Patent: August 10, 2010Assignee: Wockhardt Ltd.Inventors: Barry Knight, Stephen Knowles, Venkitraman R Srinivas, Ramesh Sesha
-
Publication number: 20090156631Abstract: The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: December 15, 2006Publication date: June 18, 2009Applicant: Wockhardt Ltd.Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Girish Kumar Jain
-
Patent number: 7482453Abstract: The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-?-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I.Type: GrantFiled: September 6, 2007Date of Patent: January 27, 2009Assignee: Wockhardt Ltd.Inventors: Mohammed Siddiqui Jaweed Mukarram, Yekanathsa Aravind Merwade, Reyaz Anjum Khan
-
Publication number: 20060293530Abstract: The present invention describes an improved process for the preparation of pure 1-(4?-Fluorophenyl)-1-(3-dimethylaminopropyl)-5-phthalanecarbonitrile and its bromide salt (citalopram hydrobromide), which is a well known antidepressant. Another aspect of the invention is isolation of crystalline (4-Bromo-2-hydroxymethyl)phenyl-(4-fluorophenyl)-3-(dimethylaminopropyl)methanol (Bromodiol) and conversion of desmethylcitalopram which is formed during the cyanide exchange reaction, to citalopram by heating with a mixture of formaldehyde and formic acid in chloroform. The resulting citalopram is purified using conventionally extraction methodology.Type: ApplicationFiled: April 28, 2006Publication date: December 28, 2006Applicant: Wockhardt Ltd.Inventors: Siddiqui Jaweed Mukarram, Bhargav Upadhye, Krishna Mishra, Mohammed Farooqui
-
Publication number: 20020061908Abstract: The invention relates to the new arginine salt forms of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating antimicrobial infections.Type: ApplicationFiled: March 9, 2001Publication date: May 23, 2002Applicant: WOCKHARDT LTDInventors: Noel J. de Souza, Shivkumar Agarwal, Mahesh V. Patel, Satish B. Bhawsar, Rupinder K. Beri, Ravindra D. Yeole, Nitin Shetty, Habil F. Khorakiwala